Lilly showcases broad Cardiometabolic pipeline with Orforglipron and once weekly insulin at ADA Scientific Sessions
Eli Lilly and Company announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the American Diabetes Association’s (ADA) 85th Scientific Sessions taking place June 20-23 in Chicago.
Lilly will also host an investor event to highlight the company’s cardiometabolic health portfolio and discuss key presentations from the ADA Scientific Sessions. The event will be held on Sunday, June 22 at 6:30 p.m. CDT and will be accessible via a live webcast on the “Webcasts & Presentations” section of Lilly’s investor website. A replay will be available on the website following the event.
Presentation Highlights
Orforglipron (investigational small molecule GLP-1 receptor agonist):
In an ADA-sponsored symposium, Lilly will share results from the ACHIEVE-1 Phase 3 trial, which evaluated the safety and efficacy of orforglipron in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone.
Insulin efsitora alfa (investigational once-weekly basal insulin):
In another ADA-sponsored symposium, Lilly will share results from the QWINT-1, QWINT-3 and QWINT-4 Phase 3 trials, which evaluated once-weekly efsitora in adults with type 2 diabetes.
Bimagrumab (investigational activin pathway inhibitor):
In a third ADA-sponsored symposium, Lilly will share results from the BELIEVE Phase 2b trial, which evaluated bimagrumab alone and in combination with semaglutide in adults with overweight or obesity without type 2 diabetes.
A selection of abstract titles and presentation details are listed below:
Orforglipron (investigational small molecule GLP-1 receptor agonist):
Presentation Title: Emerging Non-Peptide, Small Molecule GLP-1 Receptor Agonists—Can They Become Players?
Presentation Date & Time: Saturday, June 21, 8 to 9:30 a.m. CDT
Location: W375 A
Presenter: Julio Rosenstock, MD
Insulin efsitora alfa (investigational once-weekly basal insulin):
Presentation Title: Advancing and Facilitating Basal Insulin Therapy in Type 2 Diabetes—Breaking News on the QWINT 1, 3, and 4 Trials with Once-Weekly Insulin Efsitora Alfa!
Presentation Date & Time: Sunday, June 22, 1:30 to 3 p.m. CDT
Location: W375 A
Presenter: Julio Rosenstock, MD; Richard M. Bergenstal, MD; Athena Philis-Tsimikas, MD; Thomas Blevins, MD; Chantal Mathieu, MD, PhD
Tirzepatide (Zepbound and Mounjaro):
Presentation Title: Association of Tirzepatide with Kidney Parameters in People with Obesity and Prediabetes from SURMOUNT-1 over 176 Weeks
Abstract Number: 103-OR
Presentation Date & Time: Friday, June 20, 5:30 to 6:30 p.m. CDT
Location: W185 A-D
Presenter: Dr. Hiddo L. Heerspink, PhD
Presentation Title: Sustained Weight Reduction by Thresholds in Adults with Obesity and Prediabetes Treated with Tirzepatide over 176 Weeks (SURMOUNT-1)
Abstract Number: 144-OR
Presentation Date & Time: Friday, June 20, 5:30 to 6:30 p.m. CDT
Location: W196 BC
Presenter: Jamy D. Ard, MD
Presentation Title: SURMOUNT-5 Tirzepatide vs. Semaglutide for Obesity—Rapid Responders and Associated Weight Reduction and Safety
Abstract Number: 224-OR
Presentation Date & Time: Saturday, June 21, 4:30 to 6 p.m. CDT
Location: W181 A-C
Presenter: Louis Aronne, MD, FACP, DABOM
Presentation Title: Switching from Dulaglutide to Tirzepatide in T2D—Subgroup Analyses of the SURPASS-SWITCH Trial
Abstract Number: 226-OR
Presentation Date & Time: Saturday, June 21, 4:30 to 6:00 p.m. CDT
Location: W181 A-C
Presenter: Anita Kwan, MSc
Presentation Title: Patient-Reported Outcomes in People with T2D in the SURPASS-SWITCH Phase 4 Clinical Trial
Abstract Number: 227-OR
Presentation Date & Time: Saturday, June 21, 4:30 to 6:00 p.m. CDT
Location: W181 A-C
Presenter: Kristina Boye, PhD
Retatrutide (investigational GIP/GLP-1/glucagon receptor agonist):
Presentation Title: Comparative Metabolic Effects of Semaglutide, Tirzepatide, and Retatrutide in a Monogenic (db/db) Mouse Model of Obesity
Abstract Number: 2169-LB
Presentation Date & Time: Sunday, June 22, 12:30 to 1:30 p.m. CDT
Location: Poster Hall (Hall F1)
Presenter: Ansarullah, PhD
Eloralintide (investigational amylin receptor agonist):
Presentation Title: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide
Abstract Number: 849-P
Presentation Date & Time: Sunday, June 22, 12:30 to 1:30 p.m. CDT
Location: Poster Hall (Hall F1)
Presenter: Daniel A Briere
Presentation Title: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept
Abstract Number: 882-P
Presentation Date & Time: Sunday, June 22, 12:30 to 1:30 p.m. CDT
Location: Poster Hall (Hall F1)
Presenter: Edward J. Pratt, MD
Bimagrumab (investigational activin pathway inhibitor):
Presentation Title: Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide
Presentation Date & Time: Monday, June 23, 8 to 9:30 a.m. CDT
Location: W375 A
Presenters: Lee M. Kaplan, MD, PhD; Ronenn Roubenoff, MD, MHS; Penelope Montgomery, MD; Steven B. Heymsfield, MD; Louis J. Aronne, MD, FACP, DABOM; Ania M. Jastreboff, MD, PhD
About orforglipron
Orforglipron (or-for-GLIP-ron) is an investigational, once-daily small molecule (non-peptide) oral glucagon-like peptide-1 (GLP-1) receptor agonist that can be taken any time of the day without restrictions on food and water intake. Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. Chugai and Lilly published preclinical pharmacology data for this molecule together. Lilly is running Phase 3 studies on orforglipron for the treatment of type 2 diabetes and for weight management in adults with obesity or overweight with at least one weight-related medical problem. It is also being studied as a potential treatment for obstructive sleep apnea and hypertension in adults with obesity.
About insulin efsitora alfa
Insulin efsitora alfa (efsitora) is an investigational once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in Phase 3 development for adults with type 1 and 2 diabetes.
